Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Rotigotine, Rotigotine nasal spray, Efficacy, safety and tolerability, Parkinson's disease
Eligibility Criteria
Inclusion Criteria: Male and female subjects with idiopathic Parkinson's disease for at least 3 years in duration At least 30 years of age Exclusion Criteria: Patients with atypical Parkinson's or clinically relevant concomitant diseases or medical conditions
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Placebo 1
Rotigotine 1
Rotigotine 2
Rotigotine 3
Rotigotine 4
Placebo nasal spray 1 - 4 puffs
Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)
Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)
Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)
Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)